January 26, 2009 – Boca Raton, FL – NovaVision, Inc. launched a new medical device that will make it far easier for stroke and traumatic brain injury survivors with vision loss to access Vision Restoration Therapy (VRT), the only FDA-cleared therapy option that can restore neurological vision loss. In updating the medical device, NovaVision wanted to focus on two issues of concern for their patients – the cost and location of treatment.
By incorporating a diagnostic component for the non-invasive, at-home therapy device, patients can now start therapy without having to travel far from home. Once exclusively offered at 50 leading eye, neurology and rehabilitation centers nationwide, VRT can now be prescribed by any practicing neurologist, eye doctor or physiatrist. The change in technology has also meant that NovaVision can pass along savings to the patient, making Vision Restoration Therapy more affordable.
“By making changes to our medical device, we hope to help more people with neurological vision loss get their vision and lives back to normal. While we have had many motivated patients willing to fly to medical centers in the past, many survivors have either limited means or mobility and we wanted to address this,” says Rudy Mazzocchi, CEO and President of NovaVision, Inc.
About NovaVision, Inc.
NovaVision, Inc., headquartered in Boca Raton, Fla., develops and provides scientifically based, innovative medical devices and comprehensive solutions to restore the vision of patients with neurological visual impairments. FDA-cleared in 2003, NovaVision’s Vision Restoration Therapy (VRT) devices work by enhancing neuroplasticity – the brain’s ability to adapt and form new connections to compensate for injury. NovaVision’s diagnostic program maps areas where vision may be improved, and the therapy program targets and stimulates regions within the brain’s vision-processing areas.
VRT is based on more than 10 years of research with clinical studies published in leading journals including Nature Medicine, Neurology, and The Journal of Cognitive Neuroscience.Data from a recent retrospective study identified that more than 70 percent of patients who underwent VRT for an initial six-month treatment period showed measurable improvements in their vision and 88 percent of patients reported at least one activity of daily living benefit such as improved mobility or reading.VRT is
currently offered at leading neurological, eye and rehabilitation centers nationwide and can be prescribed by any eye doctor, neurologist or physiatrist.
For more information, please call 888.205.8380.
|